secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2023-06-15T23:59:59+00:00
Accession:  0001104659-23-071656
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Priveterra Acquisition receives Nasdaq deficiency notice for MVLS below $35M; adjourns special meeting
--------------------------------------------------------------------------------

- Nasdaq notified that MVLS was below $35M minimum for 30 consecutive business days; 180-day cure period ends Dec 11, 2023.
- Special meeting for AEON Biopharma business combination adjourned from June 15 to June 21, 2023 for more stockholder engagement.
- Company may consider options to regain compliance with MVLS requirement; securities continue trading during cure period.
- Proxy supplement filed; no change to record date, redemption deadline, or other proposals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000110465923071656/0001104659-23-071656-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000110465923071656/tm2318880d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-071656

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer